Replimune Group

replimune.com

Replimune Group is pioneering a novel class of oncolytic immunotherapies aimed at revolutionizing cancer treatment by activating a systemic immune response. Their proprietary Immulytic™ platform focuses on enhancing the anti-tumor effects of selective virus replication and boosting the immune response to tumor antigens. The company is developing therapies that are designed to be tolerable and effective against difficult-to-treat cancers, with multiple ongoing clinical trials evaluating their investigational therapies in various solid tumor cancers. Replimune's innovative approach positions it as a leader in the oncolytic immunotherapy space, with a strong focus on combining their therapies with other immuno-oncology products for enhanced efficacy.